Developed in the late 1980s, Chimeric Antigen Receptor Therapy, or CAR-T, has been transformative in treating patients with blood cancers. It creates a specialized treatment using a living drug to train the body’s immunological response to eliminate cancer. This new therapy provides an opportunity for patients when traditional treatment options have failed. In CAR-T, the patient’s T cells are extracted, engineered outside the body to express a specific receptor for their cancer, and infused back into the patient’s blood to fight the circulating cancer cells. This presentation compiles the analysis of both peer-reviewed journals and news articles regarding the current development of CAR-Ts and their mechanisms of action in B-cell lymphoma. I will discuss the entirety of the treatment procedure from T-cell extraction to the patient’s experience, the overall use, the availability, and the future of the therapy. Understanding the mechanisms of the treatments is essential for individualized cancer therapies.
Olivia Keven is a senior from Raleigh, NC who will be graduating in May with a B.S. in Biochemistry, a B.A. in Chemistry, and a minor in Mathematics. She hopes to pursue a Physician Assistant program and eventually specialize in Pediatric Oncology and Hematology. During her time at Salem, Olivia served as the captain of the swim team, the president of CAB, as an Admissions Ambassador, an Orientation Leader, as well as being involved with a variety of other clubs such as Rotaract and Tri Beta.